Companies ›Healthcare ›LSTA.O

LSTA.O — NASDAQ Pharmaceuticals & Medical Research

Lisata Therapeutics Inc

$1,04

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

9,5M USD

P/E

—

EV / Rev

36,7x

Div yield

—

Op margin

—

ROE

-12,6 %

Net margin

—

Debt / equity

0,00

Beta

—

52w range

—

Volume

Day range

—

Prev close

$3,30

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Lisata Therapeutics Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of chronic diseases, primarily through its proprietary drug delivery platform.

Business. Lisata Therapeutics Inc (LSTA.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

BUY3 analysts

3 buy0 hold0 sell

Avg 12m price target11,33

Analyst recommendations

3 analysts · consensus Buy

Buy3

Hold0

Sell0

12-month price target

11,33

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

3 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

-12,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning LSTA.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to LSTA.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Lisata Therapeutics Inc (LSTA.O) is a biotechnology company operating within the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals & Medical Research

AI synthesis

GENERATED

Lisata Therapeutics Inc maintains a strong liquidity position, with a current ratio of 8.92, indicating that the company has significantly more current assets than current liabilities. The company's cash and equivalents amount to $21.81 million, which is a substantial portion of its total assets of $48.24 million. The absence of long-term debt further supports the company's liquidity profile, as it does not have any long-term debt obligations to service.

The company's profitability metrics are currently negative, with a net income of -$5.40 million and an operating income of -$6.60 million. The return on equity (ROE) is -12.56%, and the return on assets (ROA) is -11.2%, both of which are below the typical thresholds for a profitable biotechnology firm. The price-to-book ratio of 0.65 suggests that the company's market value is trading at a discount to its book value, which may reflect the market's skepticism about the company's ability to generate positive returns in the near term.

Lisata Therapeutics Inc does not disclose specific revenue by business segments or geographic regions in the provided data, making it difficult to assess the company's revenue concentration. However, the company's operations are likely focused on the United States, as is common for many biotechnology firms. The lack of detailed segment data limits the ability to evaluate the company's exposure to different markets or product lines.

The company's growth trajectory is uncertain, as the provided data does not include historical revenue figures or forward-looking guidance. Analysts have provided a wide range of price targets, from $4.00 to $15.00, with a mean of $11.33 and a median of $15.00. The mean recommendation is 2.00, which is a "Buy" rating, but the absence of any "Strong Buy" ratings suggests a cautious outlook among analysts.

The risk assessment for Lisata Therapeutics Inc indicates a low level of liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and the absence of long-term debt reduces the risk of financial distress. However, the company's negative net income and operating cash flow suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders.

Recent events related to Lisata Therapeutics Inc are not detailed in the provided data. The company has not filed any recent 10-K or 10-Q reports that would provide insight into its operations or strategic direction. The lack of recent filings may indicate that the company is in an early stage of development or that it is not currently required to file regular reports with the SEC.

Key takeaways

Lisata Therapeutics Inc has a strong liquidity position with a current ratio of 8.92 and no long-term debt.
The company is currently unprofitable, with a net loss of $5.40 million and a negative ROE of -12.56%.
The company's market price of $3.08 is trading at a discount to its book value, as indicated by a price-to-book ratio of 0.65.
Analysts have provided a wide range of price targets, with a mean of $11.33 and a median of $15.00, suggesting a cautious but generally positive outlook.
The company has no immediate liquidity or dilution risks, but its negative cash flows may necessitate future capital raising.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-12

Q4 2025 · Quarter highlights

Open report →

Revenue $100.0k, −90,0% YoY; Operating income +37,8% YoY.

Revenue$100.0k−90,0 % YoY

Operating income-$3.1M+37,8 % YoY

Net income-$3.0M+35,9 % YoY

Free cash flow-$2.9M+36,1 % YoY

EPS—

Operating cash flow-$15.9M+17,6 % YoY

Financials

Income statement

Revenue$100.0k

Gross profit—

Operating income-$3.1M

Net income-$3.0M

Margins

Gross margin—

Operating margin-3079.0%

Net margin-2954.0%

FCF margin-2920.0%

Balance sheet

Total assets$17.7M

Total liabilities$2.9M

Total equity$14.9M

Cash & equivalents$16.0M

Long-term debt$0.00

Cash flow

Operating cash flow-$15.9M

CapEx-$28.0k

Free cash flow-$2.9M

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue $100.0k, −90,0% YoY
▍Operating income +37,8% YoY
▍Net income +35,9% YoY
▍Free cash flow +36,1% YoY
▍Net margin -2954.0%

Valuation TTM

Market price

$1,04

Market cap

$28.0M

Enterprise valueⓘ

$6.2M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

36.7x

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

0.7x

P / Tangible bookⓘ

0.7x

Tangible book

$43.0M

Net cashⓘ

$21.8M

Current ratioⓘ

8.9

Debt / equityⓘ

0.0

ROAⓘ

-11.2%

ROEⓘ

-12.6%

Cash conversionⓘ

130.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships7 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries7

EX21:0d697e99e830EX21:0d697e99e830Subsidiarie97%

EX21:48f7b2962e61EX21:48f7b2962e61Subsidiarie97%

EX21:6ad276361b71EX21:6ad276361b71Subsidiarie97%

EX21:84a348b7fc0eEX21:84a348b7fc0eSubsidiarie97%

EX21:bca3685fea8aEX21:bca3685fea8aSubsidiarie97%

EX21:cb5a1f8bf226EX21:cb5a1f8bf226Subsidiarie97%

EX21:d5ba48d557fbEX21:d5ba48d557fbSubsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs LSTA · multiples and returns

KLAR—

KLAR.ST

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BNTX—

Biontech SE

$92,25

23,3B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EXEL—

Exelixis Inc

$55,06

14,7B USD

P/E

19,5x

— vs self

Div yield

—

— vs self

ROE

40,4 %

+53,0 vs self

MDGL—

Madrigal Pharmaceuticals Inc

$482,00

11,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-47,8 %

-35,3 vs self

INSM—

Insmed Inc

$107,46

23,0B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-160,2 %

-147,6 vs self

VCYT—

Veracyte Inc

$45,30

3,6B USD

P/E

55,5x

— vs self

Div yield

—

— vs self

ROE

5,1 %

+17,6 vs self

MDXG—

Mimedx Group Inc

$4,27

636,0M USD

P/E

11,1x

— vs self

Div yield

—

— vs self

ROE

18,9 %

+31,5 vs self

AVIR—

Atea Pharmaceuticals Inc

$4,61

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

-57,5 %

-44,9 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,96

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,96
Revenue	—no estimate	—no estimate	—no estimate
Operating income	—no estimate	—no estimate	-29,0M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution3 analysts

Strong buy0

Buy3

Hold0

Sell0

Strong sell0

12-month price target$11,33 · Median $15,00

Low $4,00High $15,00

Operating income · consensus-29,0M USD

EPS surprise

−99,0 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$4,00

Mean$11,33

Median$15,00

High$15,00

Spot$1,04

+989.7 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

ROE-12,6 %Above median

D/E0,00Above median

Cash Conv1,30Above P75

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 67 000 sh4 grants4 insiders

Mazzo David JDirector, President & CEO · Stock Option (Right to Buy) → Common StockAcquired 40 000 @ $1,97grant · 2026-01-09
Nisco JamesSVP, Fin/Treas, Chief Actg Off · Stock Option (Right to Buy) → Common StockAcquired 7 000 @ $1,97grant · 2026-01-09
Imam TariqSVP, Bus Dev, General Counsel · Stock Option (Right to Buy) → Common StockAcquired 7 000 @ $1,97grant · 2026-01-09
Buck Kristen KEVP, R&D and CMO · Stock Option (Right to Buy) → Common StockAcquired 13 000 @ $1,97grant · 2026-01-09

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

Lisata Therapeutics Inc Market data — financials · 2026-05-28
Lisata Therapeutics Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Mixed / flat0 buys · 0 sellsnet $09 insiders · last 365d

Mazzo David JDirector, President & CEO · Common StockOther 10 515 @ $1,97$21K · 2026-01-09
Mazzo David JDirector, President & CEO · Common StockOther 12 224 @ $1,97$24K · 2026-01-09
Mazzo David JDirector, President & CEO · Common StockOther 7 854 @ $1,97$15K · 2026-01-09
Nisco JamesSVP, Fin/Treas, Chief Actg Off · Common StockOther 15 000 · 2026-01-09
Nisco JamesSVP, Fin/Treas, Chief Actg Off · Common StockOther 2 131 @ $1,97$4K · 2026-01-09
Nisco JamesSVP, Fin/Treas, Chief Actg Off · Common StockOther 1 137 @ $1,97$2K · 2026-01-09
Nisco JamesSVP, Fin/Treas, Chief Actg Off · Common StockOther 781 @ $1,97$2K · 2026-01-09
Imam TariqSVP, Bus Dev, General Counsel · Common StockOther 15 000 · 2026-01-09
Imam TariqSVP, Bus Dev, General Counsel · Common StockOther 1 401 @ $1,97$3K · 2026-01-09
Imam TariqSVP, Bus Dev, General Counsel · Common StockOther 840 @ $1,97$2K · 2026-01-09
Imam TariqSVP, Bus Dev, General Counsel · Common StockOther 747 @ $1,97$1K · 2026-01-09
Imam TariqSVP, Bus Dev, General Counsel · Common StockOther 513 @ $1,97$1K · 2026-01-09
Buck Kristen KEVP, R&D and CMO · Common StockOther 25 000 · 2026-01-09
Buck Kristen KEVP, R&D and CMO · Common StockOther 2 982 @ $1,97$6K · 2026-01-09
Buck Kristen KEVP, R&D and CMO · Common StockOther 3 221 @ $1,97$6K · 2026-01-09
Buck Kristen KEVP, R&D and CMO · Common StockOther 2 147 @ $1,97$4K · 2026-01-09
KLOSK STEVEN MDirector · Common StockOther 30 456 · 2026-01-09
HENSON HEIDIDirector · Common StockOther 30 456 · 2026-01-09
Flowers Cynthia LouiseDirector · Common StockOther 30 456 · 2026-01-09
BROWN GREGORY BDirector · Common StockOther 30 456 · 2026-01-09
AZAB MOHAMMADDirector · Common StockOther 30 456 · 2026-01-09
Mazzo David JDirector, President & CEO · Common StockOther 81 000 · 2026-01-09
Mazzo David JDirector, President & CEO · Common StockOther 10 503 @ $1,97$21K · 2026-01-09

Short positioning

129.9Kshares short+24.0% vs prior

2.81days to cover

49.1%short of daily vol

24.5Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

LSTA.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Total assets (YoY) (2025-12-31 vs 2024-12-31): -49.3%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -83.0%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -44.7%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -49.8%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 18.7%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 17.6%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 17.0%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 20.4%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 20.4%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -1.6%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.21xDerived (calculated)
Current ratio (FY 2025-12-31): 5.76xDerived (calculated)
Return on assets (FY 2025-12-31): -93.5%Derived (calculated)
Return on equity (FY 2025-12-31): -111.7%Derived (calculated)
Net margin (FY 2025-12-31): -9,756.5%Derived (calculated)
EPS (basic) (annual): USD-PER-SHARES -2SEC XBRL filing
Total assets (annual): USD 17.74MSEC XBRL filing
Total operating expenses (annual): USD 18.38MSEC XBRL filing
Operating income (annual): USD -18.21MSEC XBRL filing
Net income (annual): USD -16.59MSEC XBRL filing
Pre-tax income (annual): USD -17.55MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
Operating cash flow (annual): USD -15.95MSEC XBRL filing
Revenue (annual): USD 170KSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-06-09FILING8-K filing →

2026-06-01FILING8-K filing →

2026-05-29FILING8-K filing →

2026-05-11FILING10-Q filing →

2026-05-04FILING8-K filing →

2026-04-15FILING8-K filing →

2026-04-03FILING8-K filing →

2026-03-12 16:10 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 0.1M · Net USD -3.0M

2026-03-12 16:10 UTCEARNINGSAnnual results — FY 2026 Revenue USD 0.2M · Net USD -16.6M

2026-03-12FILING10-K filing →

2026-03-09FILING8-K filing →

2026-02-27FILING8-K filing →

2026-01-27FILING8-K filing →

2026-01-21FILING8-K filing →

2026-01-09 00:00 UTCINSIDER27 insider transactions — 2026-01 · net sell $112k 4 derivative

2026-01-09INSIDERMazzo David J transacted 10.5k sh — Director, President & CEO ~$21k

2026-01-09INSIDERMazzo David J transacted 12.2k sh — Director, President & CEO ~$24k

2026-01-09INSIDERMazzo David J transacted 7.9k sh — Director, President & CEO ~$15k

2026-01-09INSIDERNisco James transacted 15.0k sh — SVP, Fin/Treas, Chief Actg Off

2026-01-09INSIDERNisco James transacted 2.1k sh — SVP, Fin/Treas, Chief Actg Off ~$4k

2026-01-09INSIDERNisco James transacted 1.1k sh — SVP, Fin/Treas, Chief Actg Off ~$2k

2026-01-09INSIDERNisco James transacted 781 sh — SVP, Fin/Treas, Chief Actg Off ~$2k

2026-01-09INSIDERImam Tariq transacted 15.0k sh — SVP, Bus Dev, General Counsel

2026-01-09INSIDERImam Tariq transacted 1.4k sh — SVP, Bus Dev, General Counsel ~$3k

2026-01-09INSIDERImam Tariq transacted 840 sh — SVP, Bus Dev, General Counsel ~$2k

2026-01-09INSIDERImam Tariq transacted 747 sh — SVP, Bus Dev, General Counsel ~$1k

2026-01-09INSIDERImam Tariq transacted 513 sh — SVP, Bus Dev, General Counsel ~$1k

2026-01-09INSIDERBuck Kristen K transacted 25.0k sh — EVP, R&D and CMO

2026-01-09INSIDERBuck Kristen K transacted 3.0k sh — EVP, R&D and CMO ~$6k

2026-01-09INSIDERBuck Kristen K transacted 3.2k sh — EVP, R&D and CMO ~$6k

2026-01-09INSIDERBuck Kristen K transacted 2.1k sh — EVP, R&D and CMO ~$4k

Showing the 40 most recent of 65 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation TTM

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread